<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC6835697/table_3" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 3</label>
  <p>Drug combination results with GRFT.</p>
 </caption>
 <thead>
  <tr>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" id="0-0-.">Cell Line</th>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" id="0-1-.">Assay Readout</th>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" id="0-2-.">Combination Drug</th>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" id="0-3-.">Result</th>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" id="0-4-.">Ref.</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PBMCs and CD4+ MT-4 cells</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">p24 HIV-1 core Ag ELISA</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tenofovir, maraviroc, and enfuvirtide</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synergy</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[ 
    <a rid="B29-marinedrugs-17-00567" ref-type="bibr">29</a>] 
   </td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HeLa-ADA effector cells and HeLa-P5L CCR5-bearing target cells</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CCR5-tropic cell-cell fusion</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Covalently linked gp41-binding peptide C37</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synergy</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[ 
    <a rid="B32-marinedrugs-17-00567" ref-type="bibr">32</a>] 
   </td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TZM-bl cells, U87-CCR5 and U87-CXCR4.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pseudovirus neutralization</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2G12 mAb</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synergy</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[ 
    <a rid="B26-marinedrugs-17-00567" ref-type="bibr">26</a>] 
   </td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Persistently HIV-infected T cells and noninfected CD4+ target T cells</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Giant cell formation</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Efavirenz, tenofovir, raltegravir, and elvitegravir</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synergy</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[ 
    <a rid="B28-marinedrugs-17-00567" ref-type="bibr">28</a>] 
   </td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Raji.DC-SIGN cells</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DC-SIGN mediated HIV transmission</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tenofovir, saquinavir, and 2G12 mAb</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synergy</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[ 
    <a rid="B28-marinedrugs-17-00567" ref-type="bibr">28</a>] 
   </td>
  </tr>
  <tr>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MT-4 cells, PBMC</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virus-induced cytopathic effect</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microvirin, 2G12 mAb, BanLec, and HHA</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synergy</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[ 
    <a rid="B28-marinedrugs-17-00567" ref-type="bibr">28</a>] 
   </td>
  </tr>
 </tbody>
</table>
